Biopharmaceutical and pharmacokinetic aspects of hopantenic acid in pediatric pharmacotherapy
Keywords:
hopanthenic acid, biopharmacy, psychoneurological disorders, pediatricsAbstract
The development of efficient, high-quality, harmless and affordable pharmaceutical forms for drug treatment in pediatrics is a current task of contemporary pharmacy. Currently, psychiatrists and neurologists from various curative-prophylactic institutions prescribe for children and adolescents nootropic preparations in the form of tablets, powders and syrups, in various neurological diseases, the share of which, according to national and international statistics, is constantly increasing. Currently, the prescription of hopanthenic acid is gaining popularity, thanks to its neuroprotective, neurotrophic, neurometabolic, antidepressant, anxiolytic and analgesic effects. The presented paper has as starting point the analysis of the structural-molecular properties of hopanthenic acid, exposed by biopharmaceutical study, pharmacokinetic parameters and strategies for optimizing pharmaceutical formulations with gastric release.
References
1. Alzaher W., Shaw J., Al-Kassas R. Gastroretentive formulations for improving oral bioavailability of drugs: focus on microspheres and their production. Current Drug Delivery. 2016, vol. 13, nr. 5, pp. 646-661. https://doi.org/10.2174/1567201812666151012113357
2. Bakhrushina E. The prospect for the development a new combined medicinal form of hopantenic acid. Journal of New Medical Technologies eJournal. 2017. https://doi.org/10.12737/article_5a058af1129619.97429711
3. Bonner J., Pavan V., Abduljalil K. Does age affect gastric emptying time? A model-based meta-analysis of data from premature neonates through to adults. Biopharmaceutics & Drug Disposition. 2015, vol. 36, nr. 4, pp. 245-257. https://doi.org/10.1002/bdd.1937
4. Ding X., Alani A.W., Robinson R.J. Extended-release and targeted drug delivery systems. În: Remington: The Science and Practice of Pharmacy. 21st ed. Philadelphia: Lippincott Williams & Wilkins, 2005, pp. 939-950.
5. Diug E., Guranda D., Ciobanu C. Biofarmacie şi farmacocinetică. Chișinău: IP Universitatea de Stat de Medicină şi Farmacie "Nicolae Testemiţanu", Tipografia "Print-Caro", 2019. 204 p.
6. European Pharmacopoeia. 9th ed. Strasbourg: Council of Europe, 2017. p. 301.
7. Ghicavîi V., Bacinschi N., Bumacov L. Farmacologie clinică. Chișinău: CEP "Medicina" al USMF "Nicolae Testemițanu", 2009. 1068 p.
8. Ginex T., Vazquez J., Gilbert E. et al. Lipophilicity in drug design: an overview of lipophilicity descriptors in 3D-QSAR studies. Future Medicinal Chemistry. 2019, vol. 11, nr. 10. https://doi.org/10.4155/fmc-2018-0435
9. Gromova O., Torshin I., Limanova O. et al. The neurotropic, anti-inflammatory, and antitumor properties of the hopantenic acid molecule based on chemoinformatic analysis. Neuroscience and Behavioral Physiology. 2016, vol. 46, pp. 1097-1106. https://doi.org/10.1007/s11055-016-0357-z
10. Hîrjău V., Hîrjău M. Formulări farmaceutice orale cu eliberare modificată. Practica Farmaceutică. 2013, vol. 6, nr. 4, pp. 239-242.
11. Hîrjău V., Lupuleasa D., Hîrjău M. Sisteme cu eliberare modificată a substanțelor medicamentoase. În: Popovici Iu., Lupuleasa D. (eds.). Tehnologie farmaceutică. Vol. III. Iași: Polirom, 2009, pp. 653-655.
12. Calcium hopantenate. DrugBank Online. Disponibil la: https://go.drugbank.com/salts/DBSALT002703
13. Hopantenic acid. Compound Summary. National Library of Medicine. Disponibil la: https://pubchem.ncbi.nlm.nih.gov/compound/Hopantenic-acid
14. Karlina M.V., Pozharitskaia O.N., Kosman V. et al. Pharmacokinetics of hopantenic acid upon peroral administration. Eksperimental'naia i Klinicheskaia Farmakologiia. 2010, vol. 73, nr. 8, pp. 46-48.
15. Khan A.D., Bajpai M. Floating drug delivery system: an overview. International Journal of PharmTech Research. 2010, vol. 2, nr. 4, pp. 2497-2505.
16. Leucuța S.E. Biofarmacie și farmacocinetică. Cluj-Napoca: Dacia, 2002. 297 p.
17. Matcovschi C., Safta V. Ghid farmacoterapeutic. Chișinău: Vector, 2010, pp. 890-892.
18. Newton C. Global burden of pediatric neurological disorders. Seminars in Pediatric Neurology. 2018, nr. 27, pp. 10-15. https://doi.org/10.1016/j.spen.2018.03.002
19. Nicolas J.M., Bouzom F., Hugues F., Ungell A.L. Oral drug absorption in pediatrics: the intestinal wall, its developmental changes and current tools for predictions. Biopharmaceutics & Drug Disposition. 2017, vol. 38, nr. 3, pp. 209-230. https://doi.org/10.1002/bdd.2052
20. Polskaya A.V., Chutko L.S., Jakovenko E.V. The use of Pantogam syrup in treating small children's breath holding spells. Zhurnal Nevrologii i Psikhiatrii Imeni S.S. Korsakova. 2016, vol. 116, nr. 8, pp. 74-76. https://doi.org/10.17116/jnevro20161168174-76
21. Revenco N., Hadjiu S., Holban A. Intervenţia timpurie în copilărie: suport de curs. Chișinău: Print-Caro, 2019. 296 p.
22. Voloc A., Țurea V. Dezvoltarea copilului și conduita în maladiile nutriționale. Chișinău: USMF "N. Testemițanu", Tipografia Centrală, 2007, pp. 136-147.
23. Zavadenko N.N., Guzeva V.I., Gaynetdinova D.D. et al. Farmakoterapiia zaderzhki psikhomotornogo razvitiia u deteĭ 6-12 mes., rozhdennykh nedonoshennymi i perenesshikh gipoksicheski-ishemicheskoe porazhenie golovnogo mozga. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2019, vol. 119, nr. 10, pp. 30-39. https://doi.org/10.17116/jnevro201911910130
24. Zavadenko N.N., Suvorinova N.Yu., Vakula I.N. et al. Pharmacotherapy of attention deficit hyperactivity disorder in children: the results of a multicenter double-blind placebo-controlled study of hopantenic acid. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017, vol. 117, nr. 5, pp. 39-45. https://doi.org/10.17116/jnevro20171175139-45
25. Анурова М.Н., Баряева Е.А., Бахрушина Е.О. Перспективы разработки новой комбинированной лекарственной формы гопантеновой кислоты. Journal of New Medical Technologies. 2017, nr. 4, pp. 102-110. https://doi.org/10.12737/article_5a058af1129619.97429711
26. Аряев М.Л., Сеньківська Л.І. Клінічне значення гопантенової кислоти у комплексній терапії емоційних розладів у дітей, які потерпіли від психоемоційного насильства. Клінічна практика. 2013, nr. 5(139), pp. 31-34.
27. Батышева Т.Т., Квасова О.В., Быкова О.В. и др. Роль нейротрофической терапии в практике детского невролога. Методические рекомендации № 26. Москва: Научно-практический центр детской психоневрологии, 2015. 28 с.
28. Быков Ю.В., Беккер Р.А. Перспективы применения гопантеновой кислоты в психиатрической практике. Consilium Medicum. 2018, vol. 20, nr. 2, pp. 112-123. https://doi.org/10.26442/2075-1753_2018.2.112-123
29. Великодная А.В. Оптимизация стадии очистки субстанции пантогам и разработка гранулированной лекарственной формы на её основе. Магистерская диссертация. Белгород, 2018. 82 с.
30. Назаренко Н.С., Девяткина И.А., Сливкин А.И., Володина А. Разработка состава и технологии суппозиториев «Пантогам». Вестник Воронежского государственного университета. 2006, nr. 1, pp. 209-212.
31. Сливкин Д.А. Проект фармакопейной статьи «Суппозитории с пантогамом и кислотой янтарной "Пантоякс"». Вестник Воронежского государственного университета. Серия: Химия. Биология. Фармация. 2012, nr. 2, pp. 260-265.
32. Сухотина Н.К. Психическое здоровье детей и определяющие его факторы. Журнал неврологии и психиатрии им. С.С. Корсакова. 2013, vol. 113, nr. 5, вып. 2, pp. 16-22.
33. Сухотина Н.К., Крыжановская И.Л., Куприянова Т.А. Пантогам как средство профилактики пограничных психических расстройств у детей. Вопросы психического здоровья детей и подростков. 2004, nr. 4, pp. 59-63.
Downloads
Published
Issue
Section
License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
